JOURNAL OF CLINICAL SURGERY ›› 2024, Vol. 32 ›› Issue (3): 328-331.doi: 10.3969/j.issn.1005-6483.2024.03.030
Previous Articles Next Articles
ZHOU Yi,LIANG Binyong,XIAO Zhenyu
Received:
Online:
Published:
Abstract: Hepatocellular carcinoma (HCC),frequently diagnosed at advanced stages in China due to insidious onset,faces a dismal prognosis with limited surgical feasibility.The advent of immunotherapy,particularly immune checkpoint inhibitors (ICIs),introduces novel therapeutic prospects,albeit with variable efficacies.The combination of ICIs with various therapeutic strategies is increasingly recognized as a critical approach in the management of advanced HCC.This article reviews recent advances in ICIs for advanced hepatocellular carcinoma and discusses the future prospects of immunotherapy.
Key words: advanced hepatocellular carcinoma; immune checkpoint inhibitors;combination therapy
ZHOU Yi,LIANG Binyong,XIAO Zhenyu. Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma[J].JOURNAL OF CLINICAL SURGERY, 2024, 32(3): 328-331.
0 / / Recommend
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
URL: http://www.lcwkzz.com/EN/10.3969/j.issn.1005-6483.2024.03.030
http://www.lcwkzz.com/EN/Y2024/V32/I3/328
Cited